



SHORT COMMUNICATION

Suppressive Effects of Tranilast on the Expression of Inducible Cyclooxygenase (COX2) in Interleukin-1 β -Stimulated Fibroblasts

Hajime Inoue,*† Hideo Ohshima,* Hiroyuki Kono,‡ Miwa Yamanaka,*
Takako Kubota,* Masaki Aihara,* Tomoko Hiroi,‡ Nagasumi Yago‡
and Hiroto Ishida*

*DEPARTMENT OF PLASTIC AND RECONSTRUCTIVE SURGERY, AND ‡RADIOISOTOPE RESEARCH INSTITUTE FOR BASIC MEDICINE, ST. MARIANNA UNIVERSITY SCHOOL OF MEDICINE, KAWASAKI 216, JAPAN

ABSTRACT. We investigated the effects of tranilast on inducible cyclooxygenase (COX2)-mediated prostaglandin E₂ (PGE₂) production and enzyme induction in interleukin-1 β (IL-1 β)-stimulated cultured dermal fibroblasts. IL-1 β enhanced PGE₂ production in cultured fibroblasts. Tranilast did not affect constitutive cyclooxygenase (COX1) or COX2 activity in non-stimulated or IL-1 β -stimulated fibroblasts. However, the COX2 expression induced by IL-1 β was inhibited by tranilast. This result, that IL-1 β -induced COX2 expression was suppressed by tranilast, was confirmed by immunohistochemical analysis. Thus, it is possible for tranilast to regulate PGE₂ production by inhibiting COX2 induction. *BIOCHEM PHARMACOL* 53;12:1941–1944, 1997. © 1997 Elsevier Science Inc.

KEY WORDS. inducible cyclooxygenase; prostaglandin E₂; tranilast; fibroblasts

Tranilast, an anti-allergic drug [1], has been reported to suppress the hyperproliferation of granulation tissue in keloids and hypertrophic scars [2]. Tranilast is thought to mediate these effects by inhibiting collagen synthesis and/or PGE₂ production [3]. PGE₂ is also known to enhance collagen synthesis [4]. Therefore, tranilast may influence connective tissue (i.e. collagen) metabolism and inflammatory responses on keloid or hypertrophic scars by regulating arachidonate metabolism, but the mechanisms by which tranilast affects arachidonate metabolism (PGE₂ production) in human cultured normal dermal fibroblasts are not clear. It has been shown that two isozyme types (COX1 and COX2) exist in the PGE₂ production pathway [5]. COX1, which is referred to as the housekeeping enzyme, regulates mainly homeostasis, such as gastric acid secretion, whereas COX2 boosts the inflammatory response by COX2-mediated PGE₂. In the present study, we investigated the effects of tranilast on two types of cyclooxygenase-mediated PGE₂ production in cultured fibroblasts of cutaneous origin, according to the reports of Glaser and colleagues [6, 7]. In addition, we have discussed the effect of

COX2-mediated PGE₂ on keloid and hypertrophic scar formation.

MATERIALS AND METHODS

Cultivation of Fibroblasts Derived from Human Skin

Normal skin aseptically obtained during surgery was cut into 2-mm squares and sterilized twice by immersion in PBS containing antibiotics (1000 U/mL penicillin, 1 mg/mL kanamycin, and 2.5 μ g/mL amphotericin B). These sterilized fragments of skin were inoculated into culture dishes, covered with sterile cover glasses, and incubated in DMEM containing 10% fetal bovine serum at 37° in air containing 5% carbon dioxide. After confluence, cells were subcultured and the second passaged confluence fibroblasts were used for the experiments.

Influence of Tranilast on Cyclooxygenase Induction in IL-1 β -Stimulated Fibroblasts

For inhibition of endogenous cyclooxygenase, confluent fibroblasts were incubated with serum-free DMEM containing 10 μ M indomethacin for 15 min at 37° in air containing 5% carbon dioxide, and then were rinsed two times with PBS. Following the rinse, new DMEM containing 10% fetal bovine serum, 10 U/mL IL-1 β , and 100 μ M tranilast was added to the indomethacin-treated fibroblasts, and the cells were cultured for 5 hr at 37° in air containing 5% carbon dioxide. NS398 (2×10^{-7} M) and dexamethasone (4×10^{-8} M) were added to the cultured cells

† Corresponding author: Dr. Hajime Inoue, Department of Plastic and Reconstructive Surgery, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae, Kawasaki 216, Japan. Tel. 44-977-8111; FAX 44-975-3290.

§ Abbreviations: PGE₂, prostaglandin E₂; COX1, constitutive cyclooxygenase; COX2, inducible cyclooxygenase; IL-1 β , interleukin- β ; DMEM, Dulbecco's modified Eagle's medium; and ABC, avidin-biotin-complex.

Received 25 October 1996; accepted 26 February 1997.

instead of 100 μ M tranilast as a positive control. After 5 hr of cultivation, indomethacin (final concentration 10 μ M) was added to terminate the reaction. The media were promptly stored at -80° to assay for PGE₂ production.

Influence of Tranilast on Inducible Cyclooxygenase Activity in Fibroblasts

Confluent fibroblasts were incubated with serum-free DMEM containing 10 μ M indomethacin for 15 min at 37° in air containing 5% carbon dioxide and rinsed two times with PBS, as previously described. The indomethacin-treated fibroblasts were cultured for COX2 induction with DMEM containing 10% fetal bovine serum and 10 U/mL IL-1 β for 24 hr at 37° in air containing 5% carbon dioxide. After 24 hr, the medium was removed, and the IL-1 β -stimulated fibroblasts were rinsed two times with PBS to remove residual IL-1 β . DMEM (without serum) containing 10 μ g/mL bradykinin as an arachidonic acid releaser and/or 100 μ M tranilast was added to the rinsed fibroblasts, which were then incubated for stimulation of PGE₂ production at 37° in air containing 5% carbon dioxide for 60 min. NS398 and dexamethasone were also used as a positive control as described above. Specimens were stored as previously described.

PGE₂ Assay

Acetylcholinesterase-conjugated PGE₂ and PGE₂ monoclonal mouse IgGs were incubated with the specimen on micro plates precoated with goat anti-mouse polyclonal antibody, using a PGE₂ EIA Kit (Cayman Chemical Co., Ann Arbor, MI, U.S.A.) at ambient temperature for 18 hr. The plates were subsequently rinsed, and substrates for acetylcholinesterase were added to each well. After a 120-min incubation at ambient temperature, optimal density was determined with a micro plate reader (model 450, Japan Bio-Rad Co., Tokyo, Japan) at 410 nm. PGE₂ concentrations in the specimen were determined by absorbance, using calibration curves prepared simultaneously by an online data processor (Performa 575, Apple Co., Cupertino, CA, U.S.A.), and are expressed as picograms per well (mean \pm SEM). The statistical significance of differences was examined by the unpaired *t*-test.

Immunohistochemistry

After cultured fibroblasts reached confluence, the cells were subcultured on cover glasses using the same methods. The cultured fibroblasts were treated as described under "PGE₂ Assay." The fibroblasts were rinsed three times with PBS and then fixed with 4% paraformaldehyde. The fixed fibroblasts were immunostained with polyclonal rabbit anti-murine COX2 antiserum (1:50 dilution, Oxford Biomedical Research Inc., Oxford, MI, U.S.A.). A Histfine SAB-PO (for rabbit) kit (ABC system, Nichirei Co., Tokyo, Japan) was used to localize the primary IgGs with




FIG. 1. Influence of tranilast on enzyme induction of cyclooxygenase 2 in IL-1 β -stimulated normal human fibroblasts. Fibroblasts were cultured with IL-1 β and/or the experimental drugs mentioned below for 5 hr at 37° under 5% carbon dioxide. The culture medium used was DMEM containing 10% fetal bovine serum. Each value is the mean \pm SEM of four experiments. (A) Control (only DMEM), (B) tranilast (10^{-4} M), (C) dexamethasone (4×10^{-8} M), and (D) NS398 (2×10^{-7} M).

oxidized diaminobenzidine as a chromogen, followed by a Mayer's hematoxylin counterstain.

RESULTS

Influence of Tranilast on Cyclooxygenase Enzyme Induction in IL-1 β -Stimulated Normal Human Fibroblasts

PGE₂ production in normal fibroblasts incubated with IL-1 β for 5 hr was enhanced significantly compared with the control (Fig. 1). In contrast, PGE₂ production by IL-1 β -induced type cyclooxygenase (i.e. COX2) was inhibited in fibroblasts cultured in medium containing IL-1 β and tranilast under the same conditions for 5 hr. However, tranilast did not influence PGE₂ production in cultured fibroblasts under the no-IL-1 β -stimulated condition. Although NS398 and dexamethasone, used as a positive control, also inhibited COX2-mediated PGE₂ production, they did not influence it under the no-stimulated condition.

Influence of Tranilast on Inducible Cyclooxygenase Activity of IL-1 β -Stimulated Normal Human Fibroblasts

Tranilast did not affect PGE₂ production in fibroblasts stimulated by 10 μ g/mL bradykinin, i.e. PGE₂ production of COX2 activity origin (Fig. 2). In conditions where the IL-1 β -treated fibroblasts were stimulated with bradykinin, neither tranilast nor dexamethasone inhibited PGE₂ production by COX2 activity. However, NS398, a COX2 selective inhibitor, suppressed PGE₂ production in IL-1 β -treated fibroblasts.




FIG. 2. Influence of tranilast on the enzyme activity of cyclooxygenase 2 induced by IL-1 β . COX2 in fibroblasts was induced for 24 hr under the coexistence of IL-1 β at 37°. To determine COX2 activity, fibroblasts in which the enzyme was induced by IL-1 β were incubated with 10 μ g/mL bradykinin (for the purpose of releasing the substrate, arachidonic acid) and experimental drugs (see B–D) at 37° for 1 hr. Each value is the mean \pm SEM of four experiments. (A) Control (only DMEM), (B) tranilast (10^{-4} M), (C) dexamethasone (4×10^{-8} M), and (D) NS398 (2×10^{-7} M).

Immunohistochemistry

COX2-like immunoreactive proteins were detected in the cytosol of IL-1 β -stimulated fibroblasts (Fig. 3, top panel). In contrast, COX2-like immunoreactive proteins were not detected in fibroblasts treated with IL-1 β and tranilast (Fig. 3, bottom panel).

DISCUSSION

Tranilast has been used clinically for the prophylaxis and treatment of cicatricial keloids and hypertrophic scars [2, 4]. This use has been justified, as antihistamines and corticosteroids are effective in improving symptoms such as erythema or pruritus at the cicatrization site. Moreover, mast cell infiltration, a known target of tranilast, has actually been observed at the affected site [8, 9].

Some of the chemical mediators released by mast cells promote the proliferation of fibroblasts and enhance metabolism in connective tissue [10]. Therefore, drugs that inhibit the release of chemical mediators can also inhibit the activation of fibroblasts by chemical mediators. IL-1 β is known to activate fibroblasts, and it also has been detected in hypertrophic cicatricial tissue [11]. Thus, the effects of these factors on keloid formation are likely to be important. The present study was conducted to ascertain the effects of tranilast on inducible cyclooxygenase in fibroblasts stimulated by IL-1 β . PGE₂ production is suppressed by phospholipase A₂ inhibitors, such as manolide, as well as by cyclooxygenase inhibitors [12, 13]. The present results revealed that tranilast had no effect on basal PGE₂ produc-




FIG. 3. COX2-like immunoreactivity in cultured fibroblasts. Top panel: fibroblasts treated with IL-1 β . Bottom panel: fibroblasts treated with IL-1 β and tranilast. Magnification: 400 \times .

tion in fibroblasts (cultured in the absence of IL-1 β). Although NS398, used as a positive control, significantly inhibited COX2-mediated PGE₂ production in fibroblasts stimulated by IL-1 β for 24 hr, tranilast and dexamethasone had no effect. These results suggest that tranilast does not inhibit COX1 or COX2 activity. We also thought that tranilast could not inhibit phospholipase A₂ activity. However, tranilast added simultaneously with IL-1 β significantly inhibited PGE₂ production in cells stimulated with IL-1 β for 5 hr. These effects of tranilast coincided with the results showing that dexamethasone could not suppress COX2-mediated PGE₂ production but did inhibit the enzyme induction of COX2. It was also found, using immunohistochemical analysis, that tranilast could suppress the expression of COX2 protein by IL-1 β . These findings suggest that tranilast, like dexamethasone, inhibits PGE₂ production by suppressing COX2 protein synthesis.

Dermal fibroblasts are also known to enhance collagen synthesis through cytokine-induced PGE₂. Therefore, the overproduction of COX2-mediated PGE₂ causes the stimulation of collagen synthesis, in the formation of keloids and hypertrophic scars. Thus, tranilast can suppress COX2 induction, probably at the transcriptional level, and may be important in COX2-mediated processes such as uterine maturation and keloid formation [14–16].

References

1. Koda A, Nagai H, Watanabe S, Yanagihara Y and Sakamoto K, Inhibition of hypersensitivity reactions by a new drug, N(3',4'-dimethoxycinnamoyl) anthranilic acid (N-5'). *J Allergy Clin Immunol* 57: 396–407, 1976.
2. Waseda T, Arai K, Sato D, Sekine R, Sato T and Fujita K, The effect of tranilast for the treatment of hypertrophic scar and keloid. *Ther Res* 1: 155–159, 1984.
3. Suzawa H, Kikuchi S, Ichikawa K and Koda A, Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines and PGE₂ from human monocytes-macrophages. *Jpn J Pharmacol* 60: 85–90, 1992.
4. Suzawa H, Kikuchi S, Arai N and Koda K, The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. *Jpn J Pharmacol* 60: 91–96, 1992.
5. Xie WL, Chipman JG, Robertson DL, Erikson RL and Simmons DL, Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. *Proc Natl Acad Sci USA* 88: 2692–2696, 1991.
6. Glaser KB, Cyclooxygenase selectivity and NSAIDs: Cyclooxygenase-2 selectivity of etodolac (LODINE). *Inflammopharmacology* 3: 335–345, 1995.
7. Glaser K, Sung ML, O'Neill K, Belfast M, Hartman D, Carlson R, Kreft A, Kubrak D, Hsiao CL and Weichman B, Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. *Eur J Pharmacol* 281: 107–111, 1995.
8. Moriguchi T, Inoue K and Ogawa Y, Mast cell analyses in hypertrophic scars treated with triamcinolone acetone injection and those with saline solution injection alone. *Jpn J Plast Reconstr Surg* 1: 19–28, 1981.
9. Nara T, Kikuchi M and Miura Y, The fine structure of the mast cells in human scar keloid of the skin. *Jpn J Plast Reconstr Surg* 4: 141–150, 1984.
10. Smith CJ, Smith JC and Finn MC, The possible role of mast cells (allergy) in the production of keloid and hypertrophic scarring. *J Burn Care Rehabil* 8: 126–131, 1987.
11. Boxman I, Lowik C, Aarden L and Ponc M, Modulation of IL-6 production and IL-1 activity by keratinocyte-fibroblast interaction. *J Invest Dermatol* 101: 316–324, 1993.
12. Schrier DJ, Flory CM, Finkel M, Kuchera S, Lesch ME and Jacobson PB, The effects of the phospholipase A₂ inhibitor, manolide, on cartilage degradation, stromelysin expression, and synovial fluid cell count induced by intraarticular injection of human recombinant interleukin 1 α in the rabbit. *Arthritis Rheum* 39: 1292–1299, 1996.
13. Jino H, Kurahashi K, Usui H, Nakata Y and Shimizu Y, Possible involvement of endothelial leukotrienes in acetylcholine-induced contraction in rabbit coronary artery. *Life Sci* 59: 961–967, 1996.
14. Xie W, Robertson DL and Simmons DL, Mitogen-inducible prostaglandin G/H synthase: A new target for nonsteroidal antiinflammatory drugs. *Drug Dev Res* 25: 249–265, 1992.
15. Mitchell MD, Edwin SS, Lundin-Schiller S, Silver RM, Smotkin D and Trautman MS, Mechanism of interleukin-1 β PGE₂ stimulation of human amnion prostaglandin biosynthesis: Mediation via a novel inducible cyclooxygenase. *Placenta* 14: 615–625, 1993.
16. Slater D, Berger L, Newton R, Moore G and Bennett P, The relative abundance of type 1 to type 2 cyclooxygenase mRNA in human amnion at term. *Biochem Biophys Res Commun* 198: 304–308, 1994.